Profund Advisors LLC Makes New Investment in Celcuity, Inc. $CELC

Profund Advisors LLC purchased a new position in shares of Celcuity, Inc. (NASDAQ:CELC) in the 4th quarter, HoldingsChannel reports. The firm purchased 21,220 shares of the company’s stock, valued at approximately $2,116,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Creative Planning bought a new stake in shares of Celcuity in the 2nd quarter valued at $177,000. Rhumbline Advisers raised its holdings in shares of Celcuity by 1.2% during the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after purchasing an additional 503 shares during the period. XTX Topco Ltd acquired a new position in shares of Celcuity during the second quarter valued at about $169,000. Quantinno Capital Management LP raised its holdings in shares of Celcuity by 20.7% during the second quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after purchasing an additional 41,756 shares during the period. Finally, Paloma Partners Management Co raised its holdings in shares of Celcuity by 285.8% during the second quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after purchasing an additional 60,849 shares during the period. Institutional investors own 63.33% of the company’s stock.

Insider Buying and Selling at Celcuity

In other news, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the sale, the director owned 65,000 shares in the company, valued at $9,144,200. This represents a 27.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. The trade was a 57.11% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 37,000 shares of company stock valued at $5,111,950. Company insiders own 13.33% of the company’s stock.

Celcuity Stock Performance

NASDAQ CELC opened at $131.09 on Wednesday. Celcuity, Inc. has a 1 year low of $10.26 and a 1 year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The firm has a market cap of $6.39 billion, a price-to-earnings ratio of -33.61 and a beta of 0.09. The company has a fifty day moving average price of $119.52 and a 200-day moving average price of $107.75.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, equities research analysts predict that Celcuity, Inc. will post -3.87 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on CELC. Craig Hallum reiterated a “buy” rating and set a $189.00 price objective on shares of Celcuity in a report on Monday, May 4th. Stifel Nicolaus set a $150.00 price objective on shares of Celcuity in a report on Monday, May 4th. Wall Street Zen lowered shares of Celcuity from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Citigroup reiterated an “outperform” rating on shares of Celcuity in a report on Monday, May 4th. Finally, Wells Fargo & Company upped their price objective on shares of Celcuity from $150.00 to $183.00 and gave the company an “overweight” rating in a report on Friday. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $149.30.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.